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Objective: To improve medication appropriateness
and adherence in elderly patients with multimorbidity,
we developed a complex intervention involving
general practitioners (GPs) and their healthcare
assistants (HCA). In accordance with the Medical
Research Council guidance on developing and
evaluating complex interventions, we prepared for the
main study by testing the feasibility of the
intervention and study design in a cluster randomised
pilot study.
Setting: 20 general practices in Hesse, Germany.
Participants: 100 cognitively intact patients
≥65 years with ≥3 chronic conditions, ≥5 chronic
prescriptions and capable of participating in telephone
interviews; 94 patients completed the study.
Intervention: The HCA conducted a checklist-based
interview with patients on medication-related
problems and reconciled their medications. Assisted
by a computerised decision-support system (CDSS),
the GPs discussed medication intake with patients
and adjusted their medication regimens. The control
group continued with usual care.
Outcome measures: Feasibility of the intervention
and required time were assessed for GPs, HCAs and
patients using mixed methods (questionnaires,
interviews and case vignettes after completion of the
study). The feasibility of the study was assessed
concerning success of achieving recruitment targets,
balancing cluster sizes and minimising drop-out rates.
Exploratory outcomes included the medication
appropriateness index (MAI), quality of life, functional
status and adherence-related measures. MAI was
evaluated blinded to group assignment, and intra-
rater/inter-rater reliability was assessed for a
subsample of prescriptions.
Results: 10 practices were randomised and analysed
per group. GPs/HCAs were satisfied with the
interventions despite the time required (35/45 min/
patient). In case vignettes, GPs/HCAs needed help
using the CDSS. The study made no patients feel
uneasy. Intra-rater/inter-rater reliability for MAI was
excellent. Inclusion criteria were challenging and
potentially inadequate, and should therefore be
adjusted. Outcome measures on pain, functionality
and self-reported adherence were unfeasible due to
frequent missing values, an incorrect manual or
potentially invalid results.
Conclusions: Intervention and trial design were
feasible. The pilot study revealed important
limitations that influenced the design and conduct of
the main study, thus highlighting the value of piloting
complex interventions.
Trial registration number: ISRCTN99691973;
Results.
Strengths and limitations of this study
▪ This is the first randomised piloting of a complex
intervention addressing polypharmacy in primary
care.
▪ The studied complex intervention aims to
support an interaction assessment, discover
patient preferences and use a computerised
decision-support system (AiDKlinik) to prioritise
polypharmacy.
▪ The complex intervention addressed the entire
medication use process and included a health
care assistant of the general practice to empower
patients and to reduce physician’s workload.
▪ The pilot study design allowed critical proce-
dures to be implemented and all materials and
instruments for the planned main study on the
effectiveness of the complex intervention to be
tested.
▪ The pilot study design demanded considerable
effort and doubled the sample size for the feasi-
bility testing of the complex intervention.
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INTRODUCTION
Currently, as many as 80% of consultations in primary
care involve patients with multiple chronic conditions.1
Multiple disorders in patients are likely to result in the
prescription of a number of different drugs and often in
polypharmacy (>4 drugs). Polypharmacy is associated
with drug underuse, particularly in older people,2 3 and
also poses a substantial risk for adverse drug reactions
(ADR) and non-adherence, possibly leading to hospital-
isation, cognitive impairment, falls, increased mortality
and an increase in healthcare costs.4–7 About 60% of
drug-related hospitalisations are due to inappropriate
prescriptions, and about 20% to non-adherence.8 9 At
least half of these are preventable.10 11
Although interventions of proven effectiveness on clin-
ical outcomes are still lacking,12 13 promising strategies
aimed at combating inappropriate polypharmacy exist.
A ﬁrst essential step is to get a comprehensive overview of
the patient’s current medication and intake habits. This
can be accomplished by means of a so-called ‘brown bag
review’, in which patients are invited to bring all their med-
icines to the practice in their original packaging.14
Concurrently, patient adherence and hitherto unknown
prescriptions from other healthcare providers can be
assessed.15 16 This information is necessary if prescribing is
to be improved.17–19 Second, the use of computerised deci-
sion support systems (CDSS) can help ensure appropriate
prescribing.20–23 Third, preconsultation interviews provide
an opportunity for healthcare assistants (HCAs) to encour-
age older patients to tell their physicians about any
medication-related problems, thus improving adherence.24
On the basis of these strategies, we designed a complex
intervention to improve prescribing and adherence in
older patients with multimorbidity and polypharmacy in
general practice in Germany. We also included HCAs
from the participating practices. HCAs receive less train-
ing in patient care than nurses and are comparable to
certiﬁed medical assistants in the USA with regard to edu-
cation, responsibilities and remuneration.25 26 HCAs have
been repeatedly and successfully included in chronic care
interventions in Germany: under the supervision of
general practitioners (GPs), they have followed evidence-
based protocols and algorithms with ﬁxed interview ques-
tions, and have provided self-management support or
telephone monitoring for conditions such as osteoarth-
ritis, major depression and chronic heart failure.27–29
We tested the feasibility of the intervention in a
cluster-randomised controlled pilot study.30 To improve
the study design of the main study, we focused on
aspects relating to the recruitment of practices and
patients, randomisation procedures, prevention of drop-
outs and outcome measures that are relevant for subse-
quent sample size calculations for the main study.31 32
METHODS
Design and participants
We performed a cluster-randomised, controlled pilot study
with the general practice as the unit of randomisation. We
compared a complex intervention (intervention group)
with usual care (control group) with an allocation ratio
of 1:1. Treatment allocation was concealed to practices
and patients until data collection at baseline had been
completed (ﬁgure 133–58).
We invited academic teaching practices and GPs who
attended the Frankfurt General Practice Day to partici-
pate in the study. Inclusion criteria for practices were
the provision of primary care within the German statu-
tory health insurance system and that the HCA could
access the internet. A random sample of patients (for
patient recruitment, see ﬁgure 1, icons c-e) fulﬁlling the
following criteria was included: age ≥65 years, ≥3
chronic conditions, ≥5 chronic prescriptions, ≥1 prac-
tice visit during the past quarter and the ability to ﬁll in
questionnaires and participate in telephone interviews.
We excluded patients with cognitive impairment
(Mini-Mental Status Examination, MMSE <26),36
because we designed our intervention for cognitively
intact patients and did not address caregivers. Further
exclusion criteria were a life expectancy ≤6 months,
alcohol and drug abuse (based on the GP’s assessment).
Intervention and control treatment
Intervention group
The PaTplot59 (ﬁgure 1) shows the elements of the
complex intervention. It consists of a brown bag review
and a checklist-based preconsultation interview with the
patient that is conducted by the HCA (see online supple-
mentary web–appendix 1), a computer-assisted medication
review carried out by the GP and a GP-patient consultation.
GPs in the intervention group received practice guidelines
for older patients,35 and the complex intervention was
implemented at their practice on a single occasion.
Control group
GPs in the control group also received the practice guide-
lines for older patients,35 but continued with usual care.
Measurements
Feasibility of the study
The pilot study aimed to test all procedures, materials and
instruments for their suitability for use in the main study.31
32 The achievement of recruitment targets, the balance of
cluster sizes, treatment allocation and baseline character-
istics in both groups, and reasons for non-participation
and loss to follow-up of patients were examined.
Feasibility of outcome measures
Medication appropriateness index (MAI): As a potential
primary outcome to be used in the main study, we tested
the MAI, because it is widely accepted that it focuses on
patients rather than drugs and diseases.60 This ﬁtted in
well with our holistic intervention which was aimed
more at optimising medication prescriptions than on
reducing the number of prescriptions per se. The MAI
consists of 10 items: (1) indication for the drug, (2) efﬁ-
cacy for the condition, (3) correctness of dosage, (4)
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correctness of directions, (5) practicality of the direc-
tions, (6) drug–drug interactions, (7) drug-disease inter-
actions, (8) unnecessary drug duplications, (9)
correctness of treatment duration and (10) cost.61 62
Item (10) was omitted because variable discount con-
tracts between pharmaceutical and statutory health
insurers preclude cost comparisons in Germany. Items
(1) to (9) were rated for each prescription on a three-
point Likert scale (‘1’ represented appropriateness, ‘3’
inappropriateness and ‘2’ a middle rating of hardly
appropriate). Operational deﬁnitions and explicit
instructions were determined a priori for each index
item. An experienced clinical pharmacologist (SH)
coded the MAI following a blinded chart review based
on the GP’s prescriptions, multimorbidity (diagnoses,
Cumulative Illness Rating Scale—CIRS)33 34 (ﬁgure 1,
icon f) and ADR symptoms (ﬁgure 1, icon h). MAI
ratings were transformed by subtracting 1 from the ori-
ginal rating, resulting in values ranging from ‘0’ (best
rating) to ‘2’ (worst rating), and adding them up to give
an MAI score ranging from 0 to 18 per prescription.
MAI sum scores across the entire medication regimen of
the patient were calculated and the differences in the
MAI sum scores between baseline (T0) and T1 (T1-T0)
resp. T2 (T2-T0) were determined with lower MAI
scores denoting better prescribing appropriateness. A
negative value for T1-T0 or T2-T0 therefore reﬂected an
improvement in prescribing quality. Reliability of the
MAI: 6 months after T2, the clinical pharmacologist
(SH) received a sample of medication reviews for a
second rating (blinded to the results of the ﬁrst) to
determine intra-rater reliability. To explore the beneﬁt
of a second independent MAI rating, another experi-
enced clinical pharmacologist, blinded to the results of
SH, reviewed the same sample to test inter-rater reliabil-
ity. The sample was randomly drawn from T1 data until
the prespeciﬁed sample size was achieved.
We also examined health-related quality of life (EQ-5D
index),37 functional status (WHO Disability Assessment
Schedule, WHO-DAS II),38 adherence and related mea-
sures, as these are secondary outcomes that may be used
in the main trial. We collected data on self-reported
adherence according to Morisky (four items resulting in
sum scores of 0–4 points, with low scores indicating
good adherence) and the Medication Adherence Rating
Scale (MARS; ﬁve items resulting in sum scores of 5–25
points, with high scores indicating good adherence).40 42
We also measured the discrepancy between medicines
actually taken (reported at patient’s interviews) and
medicines prescribed (reported by GP). According to
Barat et al,63 we calculated (1) the drug score
(DS=number of drugs reported by the patients/number
of drugs reported by the GP), (2) the dose score
(DoS=d1(a1)+d2(a2)+d3(a3)+…/n, where di is the drug
used by the patients (value 0 or 1), n is the number of
drugs in the GP’s report, and ai is the dose-deviation rate
calculated by dividing the patient’s reported daily dose
with the daily dose reported by the GP) and (3) the
regimen score (RS=d1(b1)+d2(b2)+d3(b3)+…/n, where bi
is the regimen-deviation rate calculated by dividing the
patient’s reported daily intake frequency (once daily,
twice daily, etc.) with the corresponding frequency
reported by the GP). Scores outside an interval of 0.8–1.2
were considered to be divergent.63 Adherence-related
measures were complexity of medication (total number
of prescriptions, number of single doses/day, Medication
Regimen Complexity Index, MRCI)64 and Beliefs about
Medicines Questionnaire.41 In proxy of under-treatment,
pain intensity was measured by means of a single visual
rating scale (VRS). The numbers of days in hospital,
deaths and symptoms of side effects were analysed. We
determined the differences between baseline (T0) and
T1 (T0-T1) resp. T2 (T0-T2).
Feasibility of the intervention
We used mixed methods consisting of brief question-
naires, semistructured interviews and case vignettes
(ﬁgure 1, icons l-o and 6–10; online supplementary
web–appendix 2). All interviews were audio taped, tran-
scribed and analysed according to qualitative description
and content analysis techniques:65 66 The answers were
coded by two independent researchers and dissent was
resolved by discussion. Results were analysed according
to a previously designed coding scheme and rated as
‘feasible’, ‘not feasible’ and ‘feasible with limitations’.67
For the analysis of the case vignettes, need for technical
support with the CDSS was categorised (none, minor—
help was needed to execute a speciﬁc procedure and
major—help was needed with necessary operations).
GPs’ case vignettes were also analysed for the number of
CDSS modules used and reduction in the number of
drugs and inappropriate prescriptions.
Estimations of sample sizes
According to earlier suggestions that 30 patients per
group would allow a good estimate of mean and SD,31 68
we aimed to recruit at least 50 patients for each of the
control and intervention groups, resulting in an overall
sample size of N=100. With a target size of 5 patients per
cluster, we needed to recruit 10 GP practices per group.
This sample size also allowed the estimation of the
intracluster correlation coefﬁcient (ICC) that would be
required to support the sample size calculation for the
main study.
Inter-rater reliability in the MAI assessment ranged
from 0.47 to 0.99, and intra-rater reliability from 0.70 to
0.96.61 62 69–73 Since a less than moderate κ would be
inacceptable in our trial, we assumed the null hypothesis
value to be 0.4. With an estimated proportion of 0.3
positive ratings, a two-tailed test and 90% power, we
therefore needed N=255 prescriptions to detect a κ of
0.6 (95% CI 0.5 to 0.7).74 75
Statistical analysis
For all outcomes, the primary analysis took place accord-
ing to the intention-to-treat principle. The primary
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Figure 1 PaT plot of the PRIMUM pilot trial. GPs, general practitioners; HCA, healthcare assistant.
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comparison between the intervention and control
groups was made on the basis of the difference between
MAI scores at baseline (T0) and 6 weeks after the begin-
ning of the intervention (T1). Descriptive statistics and
ICCs are provided for the baseline characteristics of
practices and patients, as well as for the primary and sec-
ondary outcome measures. To analyse the differences
between the intervention and control groups, linear
mixed models were used. The results are presented as
adjusted (for clustering) mean differences between
groups with 95% CIs and p values, and the correspond-
ing ICCs. Since this was a pilot study, the analysis of all
result parameters remained primarily descriptive.
To determine the reliability of the MAI, the individual
ratings were dichotomised into two groups, ‘appropriate’
versus ‘inappropriate’, in accordance with earlier sugges-
tions: (1) the ratings ‘1’ and ‘2’ were considered to be
‘appropriate’ and ‘3’ ‘inappropriate’,62 76 (2) prescriptions
rated as ‘1’ were considered ‘appropriate’ and those rated
as ‘2’ or ‘3’ ‘inappropriate’.71 Observer agreement and
chance-adjusted agreement were calculated using
κ-statistics, and alternative measures, such as the B-statistic
and prevalence-adjusted bias-adjusted κ (PABAK), when
the prevalence of positive ratings was low.77–79
RESULTS
Feasibility of the study
Recruitment and maintenance
Of the 692 potentially eligible patients from 20 general
practices, 230 were selected at random and 100 were
included (ﬂow chart: online supplementary web–appen-
dix 3). Of the 130 patients not included in the study, 67
were not invited because the recruitment target had
already been reached, 41 did not meet the inclusion cri-
teria, 20 refused to participate and 2 gave no reasons. In
the intervention group, one patient at T1 (hospitalised)
and four patients at T2 (three were hospitalised, one
refused further participation) were lost to follow-up. In
the control group, we lost two patients at T1 and subse-
quently at T2 (one died, one switched GP).
Study population
The GPs were mostly male (75%), had a median age of
57 years (range: 40–62 years) and were clinically experi-
enced (on average 22 years). The median age of the
HCAs was 42 years (20–58 years), and of the patients
75 years (64–93 years). The baseline characteristics of
the study population are shown in table 1.
Outcome measures
At baseline, the outcome measures were balanced in
both groups (table 2). Medication appropriateness: The
vast majority of MAI ratings was ‘appropriate’ (see
online supplementary web–appendix 4) and changes in
mean MAI scores were small in both groups (table 3).
Based on B-statistics, the intra-rater reliability for the
MAI items ranged from 0.90 to 0.99, and inter-rater
reliability from 0.83 to 0.94 (see online supplementary
web–appendix 4). Mean differences in secondary out-
comes between groups were small with wide two-sided
95% CIs. There was also no consistent trend across mea-
sures (table 4). Completeness of data: Outcome mea-
sures based on data from case report forms and patient
telephone interviews including the MAI could be ana-
lysed almost completely. The proportion of missing
values in secondary outcomes based on data from
patient questionnaires ranged from 5% to 10% at base-
line, 6% to 11% at T1 and 10% to 14% at T2. The VRS
had the highest number of missing values (table 4).
Feasibility of the intervention
Perspective of GPs
In short questionnaires (ﬁgure 1, icon l), GPs reported a
median time requirement of 35 min (IQR: 25—60′) per
patient and that they were very satisﬁed or satisﬁed with
39/49 (80%) interventions, rather satisﬁed with 7/49
interventions (14%) and rather dissatisﬁed with 1/49
interventions (2%). Two interventions were not assessed.
In semistructured interviews, 10 GPs (ﬁgure 1, icon 7)
described the intervention as feasible or feasible with lim-
itations: 9/10 reported positive experiences using the
CDSS (‘it is clearly structured, it is well-arranged’; ‘I liked
… the weightings (for alerts)’), 1/10 did not (‘I did not
feel comfortable with this programme…because I did not
completely understand it’.). Five of 10 GPs reported that
the GP–patient consultation was a positive experience
(‘clearly more systematic than regular consultations’;
‘more often focused on adverse effects’; ‘cooperation
with patients has been improved’) and 9/10 GPs experi-
enced improved communication with HCAs (‘I certainly
talked more with the HCA about one or the other patient
… because she wanted to give her feedback’).
With the case vignettes (ﬁgure 1, icon 8), 7/10 GPs
needed support in using the CDSS (support with a spe-
ciﬁc command: 5/7, major support: 2/7). To optimise
medication for the case vignette, GPs used on average
two of the four available CDSS alert functions (ﬁgure 1,
icon 4). The number of prescriptions fell by 58%, poten-
tially severe drug–drug interactions by 86% and inappro-
priate renal dosage adjustments by 71%. Inappropriate
non-steroidal anti-inﬂammatory drugs prescriptions for
the case vignette were stopped by 6/10 GPs and substi-
tuted with appropriate analgesics by 3/10 GPs. The tech-
nical usability of the CDSS (ﬁgure 1, icon n) was rated
by GPs in median with ‘good’ for learnability (IQR:
1.25–2), clarity (1–2) and handling (2–2.75). The tech-
nical usability of the CDSS in everyday practice was
assessed in median 4.5 (IQR 2.25–5) and GPs reported
in interviews that the ‘poor’ rating was mainly due to a
lack of connectivity with their practice software systems
and the amount of time required.
Perspective of HCAs
In short questionnaires (ﬁgure 1, icon m), HCAs
reported a median time requirement of 45 min (IQR: 33
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Urban 4 (40) 2 (20)
Suburban 5 (50) 4 (40)
Rural 1 (10) 4 (40)
Single-handed practices: number (%) 6 (60) 4 (40)
Panel size: number (%)
Fewer than 1000 4 (40) 1 (10)
1000–1499 6 (60) 5 (50)
1500 or more 0 4 (40)
General practitioners
Age (mean, SD) 54.8±7.41 54.25±5.31
Male sex: umber (%) 7 (70) 8 (80)
Board certificate: number (%) 10 (100) 9 (90)
General practitioner/general internist 7 (70)/3 (30) 7 (70)/2
(20)
Years of clinical experience (mean, SD) 22.6±11.44 20.6±8.55
Years at practice site (mean, SD) 19.3±8.83 18.4±10.20
Healthcare assistants
Age (mean, SD) 40.0±11.81 39.2±13.64
Female sex: number (%) 10 (100) 10 (100)
Years of professional experience 18.8±12.2 16.3±10.56
Years at practice site 12.0±9.61 9.6±9.84
Full-time employment: number (%) 5 (50) 4 (40)
Patients n=50 n=50
Age (mean, SD) 75.8±6.70 75.2±5.88
Female sex: number (%) 28 (56) 24 (48)
Covered by statutory health insurance: number (%) 46 (92) 50 (100)
Living with spouse or family: number (%) 32 (64) 35 (70)
Fending for themselves: number (%) 46 (94) 45 (92)
Home care situation good or very good (GP assessment): number (%) 44 (88) 44 (90)
CIRS sum score (mean, SD) 10.6±4.38 9.4±4.20
CIRS number of affected organ systems (mean, SD) 6.0±2.38 5.7±2.37
Number of chronic diseases* (mean, SD) 8.4±2.52 7.0±2.62
Charlson comorbidity score 4.5±2.64 4.5±2.46
Most common chronic diseases†: number (%)
Hypertension including end organ affection 45 (90) 41 (82)
Diabetes mellitus 27 (54) 32 (64)
Lipid metabolism disorders 25 (50) 27 (54)
Chronic ischaemic heart disease 25 (50) 21 (42)
Osteoarthritis, joint arthrosis 17 (34) 18 (36)
Atherosclerosis/peripheral arterial disease 21 (42) 14 (28)
Asthma/chronic obstructive pulmonary disease 16 (32) 16 (32)
Cardiac arrhythmias 20 (40) 10 (20)
Gout and hyperuricaemia 23 (46) 6 (12)
Thyroid dysfunction 16 (32) 11 (22)
Chronic heart failure 11 (22) 13 (26)
Chronic gastro-oesophageal disease 13 (26) 11 (22)
Vision problems 11 (22) 12 (24)
Mental illnesses 9 (18) 13 (26)
Liver diseases 13 (26) 8 (16)
Falls: number of patients (%) 7 (14) 6 (12)
Previous hospitalisation: number of patients (%) 13 (26) 12 (24)
Number of previous days in hospital (mean, SD) 2.6±6.05 3.1±8.78
Potential ADR symptoms‡: number (%)
Bleeding diathesis§ 18 (37) 15 (30)
Ankle oedema 15 (31) 20 (40)
Continued
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—70′) and were very satisﬁed or satisﬁed in 92% of
cases (45/49), and rather satisﬁed in 2/49 cases (4%).
No intervention was considered rather dissatisfying or
worse, and two interventions were not assessed. In semi-
structured interviews, HCAs (ﬁgure 1, icon 9) reported
no major problems with the intervention and positive
experiences with the patients: 9/10 HCAs had no difﬁ-
culties using and ﬁlling out the MediMoL (‘I really had
no problems, it all went well’), one had difﬁculties (‘Not
all the questions were clear to me’). The CDSS per-
formed well: 9/10 HCAs described the experience as
‘very good’ (‘I could use it very easily, I am doing ﬁne
with it’), one considered the experience ‘rather good’
(‘It would be nice, if (the CDSS) would transfer (the
medication) …from Medibox 1 to Medibox 2’). The
HCAs felt the investigator and intervention trainings
(ﬁgure 1, icons 1 and 2) prepared them well for the







Dizziness§ 13 (27) 11 (22)
Dyspnoea§ 8 (16) 12 (24)
Difficulties urinating 6 (12) 10 (20)
Abdominal pain§ 5 (10) 4 (8)
Tachycardia or palpitation§ 4 (8) 4 (8)
Nausea or vomiting§ 4 (8) 3 (6)
*Disease count according to the list of chronic diseases by Schafer et al.87
†Chronic diseases87 prevalent in more than 20% of the total study population in descending order.
‡Symptoms appeared on several days or almost every day.
§For details, see figure 1.
ADR, adverse drug reaction; CIRS, Cumulative Illness Rating Scale; GP, general practitioner.







ni Mi (SD) nc Mc (SD) ICC/ICCadj
MAI 50 5.0 (4.69) 50 4.8 (5.40) 0.085/0.099
EQ-5D, index 45 0.80 (0.19) 48 0.80 (0.18) 0.000/0.006
VRS 43 4.8 (2.37) 47 4.4 (2.67) 0.021/0.029
GDS 49 2.2 (2.12) 49 1.7 (1.89) 0.029/0.025
Number of drugs 50 9.5 (2.67) 50 8.7 (2.66) 0.186/0.180
Number of single doses 50 9.5 (3.19) 50 9.4 (3.83) 0.177 0.192
MRCI 50 13.8 (7.21) 50 13.7 (5.98) 0.048/0.060
Number of ADR symptoms 49 1.9 (1.62) 50 1.8 (1.44) 0.031/0.040
Observed adherence*
Drug score (%)† 48 20 (41.7) 49 23 (46.9) 0.003/0.001
Dose score (%)† 46 45 (97.8) 48 48 (100) −/−‡
Regimen score (%)† 45 45 (100) 48 48 (100) −/−‡
Reported adherence
MARS 46 23.9 (1.68) 47 24 (1.16) 0.0004/0.008
Morisky 49 0.3 (0.69) 50 0.2 (0.48) 0.000/0.000
BMQ
Specific necessities 45 22.4 (3.26) 48 22.5 (2.57) 0.000/0.000
Specific concerns 44 14 (5.52) 47 13 (4.91) 0.000/0.000
General overuse 44 10.3 (4.77) 47 10.4 (3.88) 0.000/0.006
General harms 47 7.8 (3.40) 48 7.6 (3.30) 0.000/0.000
Numbers of patients (n), mean (M), SD and intracluster correlation coefficients (ICCs) are provided, the latter as crude values and adjusted for
groups.
*Discrepancy between medication actually taken (reported at patient’s interviews) and medication prescribed (reported by GP).
†Number and percentage of deviating patients.
‡No ICC could be estimated, as (almost) all patients were scored as deviating.
ADR, adverse drug reaction; BMQ, Beliefs in Medicine Questionnaire; CIRS, Cumulative Illness Rating Scale; GDS, Geriatric Depression
Scale; MAI, Medication Appropriateness Index; MARS, Medication Adherence Rating Scale; MRCI, Medication Regimen Complexity Index;
VRS, Visual Rating Scale (pain assessment).
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Table 3 Outcome MAI
Intervention group Control group
MAI sum score at patient level ni Mi (SD) Mediani (IQR) nc Mc (SD) Medianc (IQR) ICC/ICCadj p Value
T0 50 5.0 (4.69) 3.5 (2–6.75) 50 4.8 (5.40) 3 (1–6.75) 0.085/0.099 0.882
T1 48 5.1 (5.12) 4 (1–7.25) 48 4.2 (5.09) 2 (0–7) 0.000/0.000 0.401
T2 46 5.7 (6.57) 3 (1–7) 47 4.6 (4.76) 3 (1–7) 0.049/0.053 0.387
MAI sum score T1-T0 48 0.1 (5.31) 0.5 (−3–3) 48 −0.6 (5.56) 0 (−2.25–1.25) 0.023/0.032 0.548
MI-MC (95% CI), not adjusted −0.7 (−1.6 to 0.2)*
MI-MC (95% CI), adjusted for clustering −0.7 (−3.0 to 1.6)*
MAI sum score T2-T0 46 0.7 (5.45) 0 (−2–3) 47 −0.2 (5.17) 0 (−2–2.5) 0.030/0.039 0.460
MI-MC (95% CI), not adjusted −0.9 (−1.8 to 0.1)*
MI-MC (95% CI), adjusted for clustering −0.9 (−3.2 to 1.4)*









T0 130/439 29.6 108/412 26.2
T1 109/415 26.3 90/385 23.4
T2 107/393 27.2 99/371 26.7









T0 2.60 (1.67) 0.30 (0.18) 2.16 (1.80) 0.25 (0.19)
T1 2.27 (1.82) 0.26 (0.20) 1.875 (1.81) 0.22 (0.20)
T2 2.33 (1.89) 0.26 (0.20) 2.11 (1.82) 0.24 (0.20)
If not stated otherwise, mean (M) and SD are provided. ICCs are provided as crude values and adjusted for group. p Values are adjusted for cluster effects.
*The trend was in favour of the control group.



























ni Mi (SD) nc Mc (SD) ICC/ICCadj p Value Mi—Mc (95%-CI) ni Mi (SD) nc Mc (SD) ICC/ICCadj p Value Mi—Mc (95%-CI)
EQ-5D, index 40 0.0 (15.89) 42 2.4 (17.85) 0.022/.037 0.531 2.5 (−5.2 to 10.3) 40 −0.6 (19.61) 36 −1 (13.66) 0.000/0.000 0.926 −0.4 (−8 to 7.3)
VRS 36 0.0 (1.71) 42 0.0 (2.32) 0.000/0.008 0.968 0.0 (−0.9 to 0.9) 36 0.0 (1.84) 37 0.0 (2.69) 0.000/0.008 0.968 0.0 (−0.9 to 0.9)
GDS 46 −0.1 (1.84) 46 0.4 (1.71) 0.000/0.000 0.193 0.5 (−0.2 to 1.2) 43 −0.4 (1.92) 46 1.2 (2.28) 0.201/0.098 0.006 1.6 (0.6 to 2.7)
Number of drugs 49 −0.1 (2.41) 48 −0.4 (1.39) 0.000/.000 0.569 −0.2 (−1.0 to 0.6) 46 −0.7 (1.56) 47 −0.4 (1.43) 0.063/0.069 0.497 0.2 (−0.4 to 0.9)
Number of single doses 49 −0.1 (2.21) 48 −0.3 (2.8) 0.140/0.153 0.753 −0.2 (−1.5 to 1.1) 46 0.2 (1.79) 47 −0.4 (2.65) 0.060/0.062 0.302 −0.6 (−1.6 to 0.5)
MRCI 49 1.3 (5.43) 48 0.3 (3.26) 0.079/0.078 0.374 −1.0 (−3.0 to 1.1) 46 1.4 (5.24) 47 0.6 (4.91) 0.091/0.100 0.555 −0.7 (−3.2 to 1.7)
Number of ADR symptoms 46 0.1 (1.48) 47 0.2 (1.30) 0.131/0.147 0.844 −0.1 (−0.7 to 0.8) 43 0.0 (1.02) 47 −0.2 (1.34) 0.084/0.093 0.569 −0.2 (10.8 to 0.4)
Observed adherence*:
Drug score (%) 45 0.0 (0.35) 47 0.1 (0.28) 0.054/.065 0.560 0.0 (−0.1 to 0.2) 42 0.0 (0.33) 46 0.0 (0.28) 0.128/0.142 0.636 0.0 (−0.1 to 0.2)
Dose score (%) 42 0.0 (0.23) 45 0.0 (0.21) 0.042/.051 0.570 0.0 (−0.1 to 0.1) 39 0.0 (0.23) 45 0.0 (0.21) 0.033/0.047 0.959 0.0 (−0.1 to 0.1)
Regimen score (%) 41 0.0 (0.14) 45 0.0 (0.18) 0.000/.000 0.977 0.0 (−0.1 to 0.1) 38 0.0 (0.14) 45 0.0 (0.19) 0.000/0.000 0.761 0.0 (−0.1 to 0.1)
Reported adherence:
MARS 42 0.0 (1.64) 43 −0.1 (1.18) 0.000/0.000 0.944 0.0 (−0.6 to 0.6) 43 −0.2 (1.79) 37 0.1 (1.14) 0.000/0.000 0.484 0.2 (−0.4 to 0.9)
Morisky 46 −0.1 (0.64) 47 0.0 (0.55) 0.000/0.000 0.237 0.2 (−0.1 to 0.4) 43 0.0 (0.79) 47 0.0 (0.47) 0.000/0.000 1.00 0.0 (−0.3 to 0.3)
BMQ:
Specific necessities 42 −0.4 (2.84) 43 −0.7 (3.55) 0.047/0.056 0.693 −0.3 (−1.8 to 1.2) 40 0.1 (3.59) 38 −1.0 (4.72) 0.231/0.239 0.277 −1.4 (−3.9 to 1.1)
Specific concerns 40 −1.2 (5.03) 42 −0.9 (5.35) 0.185/.200 0.934 0.1 (−2.8 to 3.0) 39 −1.3 (6.17) 36 −1.6 (5.43) 0.275/0.294 0.724 −0.7 (−4.3 to 3)
General overuse 39 0.1 (3.18) 40 −0.1 (2.76) 0.000/.000 0.766 −0.2 (−1.5 to 1.1) 39 0.2 (4.18) 37 −0.8 (2.42) 0.000/0.000 0.251 −0.1 (−1.9 to 1.7)
General harms 44 0 (2.26) 41 −0.4 (2.85) 0.000/0.000 0.395 −0.5 (−1.6 to 0.6) 42 −0.2 (3.45) 36 −0.5 (3.17) 0.000/0.012 0.664 0.2 (−1.2 to 1.5)
Number of hospital stays† 50 −0.4 (0.73) 50 −0.2 (0.62) – – – – – – –
Days in hospital† 50 −0.4 (0.73) 50 −0.2 (0.69) – – – – – – –
If not stated otherwise, mean and SD are provided. ICCs are provided as crude values and adjusted for group. p Values are adjusted for cluster effects.
*Discrepancy between medication actually taken (reported at patient’s interviews) and medication prescribed (reported by GP).
†Hospitalisations are aggregated for both follow-ups: T1+T2−T0; due to low event rates and skewness of distribution; no ICCs, p values and mean differences are provided.
ADR, adverse drug reaction; BMQ, Beliefs in Medicine Questionnaire; CIRS, Cumulative Illness Rating Scale; GDS, Geriatric Depression Scale; ICCs, intracluster correlation coefficients; MAI,



















structured; I had no problems’). The encounter with
the patient was assessed particularly positively (‘I really
liked being allowed to do the tests on the patients and
being able to work so closely with them’).
The case vignette (ﬁgure 1, icon 10) was understood
by 6/10 HCAs without any help, while 4/10 HCAs
needed minor support (eg, to enter the name of a com-
plementary drug formulation in Medibox 2). The tech-
nical usability of the CDSS (ﬁgure 1, icon o) was rated
by the 10 HCAs in median with ‘good’ for all dimen-
sions, with the IQR regarded as slightly better for learn-
ability and handling (1.25–2) than for clarity and
workaday practicability (2–2).
Patients’ perspective
In telephone interviews, 23/42 patients knew what the
study was about and explained the potential beneﬁts for
themselves (‘Drug tolerance and interactions between
different drugs are looked at, to see if there might be
one that could be left out’), whereas the remaining
patients did not understand the study and did not feel
they had beneﬁted from participating in it (‘I’m not
reckoning on beneﬁting from it personally, but my
doctor asked me to’). None of the patients said that any
of the questions asked by the HCA in the preconsulta-
tion interview had made them feel uneasy. Patients’
symptoms were mostly about the study methods (‘Being
asked twice about medicines; only one of mine was
dropped; that could have been decided quicker’; ‘It’s
difﬁcult to answer all the questions in the questionnaire
with a simple yes or no’).
DISCUSSION
The complex intervention to prioritise and optimise
multimedication in older patients with multimorbidity,
and the study design, are feasible in a general practice
setting. However, the pilot study revealed a number of
limitations and potential barriers to the future imple-
mentation of the complex intervention that should be
addressed when designing the main trial.
Feasibility of the complex intervention
Participating GPs valued the structured systematic
approach to conducting consultations and said working
relationships with patients and HCAs had improved.
HCAs appreciated being involved in the complex inter-
vention. Both GPs and HCAs reported mainly positive
experiences with the tools MediMoL and the CDSS and
rated the (technical) usability of the CDSS as ‘good’.
Moreover, GPs were often surprised by the discrepancy
between prescribed and taken medicines, as conﬁrmed
by the brown bag review. Only slightly more than half
the study patients were fully aware of the rationale and
the aims of the study. However, informed patients wel-
comed the chance to detect inappropriate prescriptions
and to adjust their medication. Nevertheless, GPs
pointed out that the process required considerable time
and said the incompatibility of the CDSS with their prac-
tice software was a relevant barrier to future practice
implementation. Positive results in interviews and ques-
tionnaires differed somewhat from the situation with
case vignettes where difﬁculties were experienced using
the CDSS application: more GPs than HCAs needed
help in using the features and running the programme.
Most HCAs and GPs did not use the CDSS following the
completion of the ﬁnal intervention, so their difﬁculties
may have resulted from a lack of training and the time
lag between the ﬁnal intervention and the case vignette
(ﬁgure 1). Since we did not provide a manual, it is pos-
sible that not all practices correctly implemented the
CDSS.
Feasibility of the trial design
Most procedures went well—recruitment was completed
with equal cluster sizes, randomisation resulted in
overall balanced groups, loss to follow-up was within
acceptable limits and data collection and the medication
reviews by the clinical pharmacologist were feasible.
Missing data were most common in patients’ question-
naires, and in the VRS in particular. Patients’ interviews
showed that some patients had difﬁculties understand-
ing questions from the validated instruments. The most
relevant outcome measures, MAI and EQ-5D, showed an
almost perfect baseline value, leaving little room for
improvement. First, cardiovascular comorbidity was
highly prevalent, with common diseases sharing the
same pathways and treatment targets. This may have pre-
vented GPs from having to deal with potentially harmful
interactions. Second, a reduction in inappropriate pre-
scriptions was observed in both groups, indicating a
likely contamination effect in the control group: both
groups received the study protocol including a detailed
description of the intervention. Although the CDSS was
only available to the intervention group, the control
group may have conducted brown bag reviews and medi-
cation reviews with or without computer support. Some
practice software provides alert features for drug–drug
interactions. However, these are often deactivated due to
over-alerting.80
Furthermore, the low prevalence of ‘inappropriate
prescriptions’ and imbalanced marginals for MAI ratings
in our sample led to paradoxically low κ values despite
high intra-rater and inter-rater observer agreement.79 In
this situation, alternative reliability measures such as
B-statistics and PABAK are recommended.77–79 Using
these measures, intra-rater reliability of MAI ratings
showed almost perfect agreement81 and intra-rater reli-
ability was slightly better, which is in line with former
observations.62 69 73 Evaluated secondary outcomes
showed small changes but supported for most of them a
further use in the main study (EQ-5D and
adherence-related measures such as medication com-
plexity). As observed in earlier studies,82 measures of
self-reported adherence did not appear to provide valid
results, as they contradicted results from comparisons of
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prescribed with taken medicines, and showed ceiling
versus ﬂoor effects. Additionally, MARS had a large
number of missing values. The functionality outcome
(WHO-DAS II) was not usable, because the manual was
under development and did not provide a correct
formula.
The application of the cluster-RCT design was both a
strength, because it allowed to put in place all proce-
dures of the planned main study, and a challenge,
because the integration of a control group doubled the
sample size for feasibility testing of the complex inter-
vention. Furthermore, participants may have overesti-
mated the time required by the intervention because
the time required for data collection and other proce-
dures may have been included in estimates of the time
required to perform the complex intervention. With the
use of mixed methods, however, we were able to identify
obstacles to the complex intervention and its implemen-
tation that helped us to improve the design of the main
study. The CDSS recorded data on use (eg, date of use,
completion of Mediboxes by GPs/HCAs), but these data
did not provide information on whether or not the users
correctly applied the different features to check for
interactions, appropriate dosage, etc. In qualitative inter-
views, GPs and HCAs did not report problems using the
CDSS when asked. However, case vignettes helped
detect difﬁculties experienced by GPs and HCAs in the
use of the new software. These can be eliminated by
intensifying training and providing supporting material.
Limited resources prevented us from gaining detailed
insights into usual care provided by GPs when adjusting
medication for older multimorbid patients, and this is a
further limitation of our study. This information could
have been helpful in planning the main trial.
This article provides the results of the systematic pilot-
ing of a complex intervention for polypharmacy and its
corresponding trial design in primary care. Published
trials on complex interventions in polypharmacy
included in a current Cochrane review were not piloted
at all or mentioned only a piloting phase without
describing results and conclusions.12 Many of the studies
were conducted after publication of the MRC guidance
that strongly recommends a piloting phase.30 83 Very
recently, Clyne and coauthors reported on an alternative
approach, also aimed at helping in the development of
a complex intervention to reduce potentially inappropri-
ate prescribing (PIP), but which uses explicit criteria.84
The authors described an exhaustive consensus process
for deriving an acceptable set of PIPs from lists identi-
ﬁed in a literature review (eg, Beers and STOPP cri-
teria85 86). Focusing on a high acceptability at the
provider level, the authors applied predominantly quali-
tative methods that resulted in the stepwise improve-
ment of the intervention. Our approaches differed
mainly in purpose, methods and (presumably) in cost
but both highlight the fact that descriptions of piloting
phases are particularly useful for a number of reasons:
they typically use more diverse techniques than full
studies, uncover critical pitfalls and challenges and
provide important insights into promising techniques,
facilitators and barriers and often also into the causes of
success and failure.
Lessons learnt
Feasibility testing of our complex intervention has
enabled us to improve the design of the main study: as a
consequence, investigator training has been intensiﬁed
and supported by a written manual with a strong focus
on using the CDSS. The multitude of used interfaces
will prevent signiﬁcant improvement in connectivity to
practice software systems in the main study. The
National Association of Statutory Health Insurance
Physicians has only recently begun to work on harmonis-
ing data interfaces for manufacturers of practice soft-
ware, thus facilitating future data exchange with systems
such as our CDSS.
Feasibility testing identiﬁed a potential contamination
problem with the control group. We have therefore
decided that in the main study, no details of the inter-
vention will be shared with healthcare professionals of
the control group. Furthermore, we have changed the
inclusion criteria. To include a greater number of
patients at risk of (manageable) interactions, patients
have to have not only three or more chronic diseases,
but the diseases must be from at least two different chap-
ters of ICD-10. We have also replaced impractical
outcome measures (VRS, WHO-DAS II and MARS).
Although we have demonstrated feasibility and poten-
tial limitations of the complex intervention, its effective-
ness in general practice has yet to be proven.
Furthermore, it is as yet unclear whether the advantages
will outweigh the disadvantages in terms of required
time and costs, and whether the barriers to a wider
implementation in routine care can be removed.
CONCLUSION
Our pilot study of a complex intervention to prioritise
and optimise multimedication in older patients with
multimorbidity has conﬁrmed the feasibility of the inter-
vention and the study design, but has also revealed
rather important limitations and options for improve-
ment. These have enabled us to reﬁne and modify the
ﬁnal design and improve the main study in critical areas
such as measures to limit contamination, inclusion cri-
teria and outcome measures.
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